And one thing that will bring prices down, and help with availability, and help the PBS in making its decision based on cost benefits, is competition. Whatever happens, the important thing will be the recognition that this is a chronic, relapsing condition. It's not the individual's fault, but the individual is suffering the consequences
Time to first intensification with any treatment was calculated using competing risk analysis
Fetching molecular profile BPC-157/TB-500/GHK-Cu/KPV BlendAlso known as: Body Protection Compound (BPC-157), Thymosin Beta-4 (TB-500), Copper Peptide (GHK-Cu), Lysine-Proline-Valine (KPV) Mechanism of Action This blend combines synergistic peptides targeting multiple regenerative pathways: BPC-157 promotes tissue healing by inducing vascular endothelial growth factor (VEGF), enhancing angiogenesis and cytoprotection
It is remarkable that these results were obtained in a population of patients with an overall preserved eGFR (mean 86 ml/min per 1.73 m 2 )